Australian spinout eyes the clinic with a prophylactic nasal spray for Covid-19
MRCF 5 - MRCF5 provides seed stage investment for early-stage life science opportunities associated with MRCF Member organisations. MRCF5 has the capacity to continue to support opportunities into clinical development and commercialisation.
MRCF BTF - The MRCF BTF is focussed on supporting clinical stage, Australian, biomedical opportunities.
MRCF3 - MRCF3 provides seed stage investment for early-stage life science opportunities associated with MRCF Member organisations. MRCF3 has the capacity to continue to support opportunities into clinical development and commercialisation.
MRCF1 and MRCF2 (MRCF IIF, LP and MRCF Trust) - now fully invested
Brandon Biosciences Fund 1 (BBF1 IIF and BBF1 Trust) - now fully invested
Combining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
George Medicines is an innovative late-stage drug development company focused on the large, expanding and underserved market for the management of non-communicable diseases (NCDs)
Unlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
High Quality Serum for Biochemistry Analysis: A proprietary blood collection tube rapidly providing high quality serum for analysis from all bloods including anti-coagulated.
Ena Respiratory is a biotechnology company aiming to transform the treatment and prevention of respiratory infections. The company initial focus is to target respiratory infections in patients with asthma and COPD.
ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Fund Raise
Preclinical studies from Vaxxas and Collaborators Reveal Potential of Vaxxas’ Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine